Skip to main content
SpringerLink
Log in

Botulinum Toxin for New Indications

Botulinum Toxins, Fillers and Related Substances

  • 223 Accesses

Abstract

Since it was first approved by FDA for the treatment of glabellar frown lines, botulinum toxin rapidly became one of the most popular cosmetic procedures. In the last decade, its use has increased with improved techniques and new indications in the medical and cosmetic field. These include the treatment of asymmetries, muscles hypertrophy, and different conditions aggravated by sweating, keloids, and some diseases, as depression, rosacea, oily skin and associated conditions, and Raynaud’s phenomenon. Besides its effects in different conditions, new uses might be developed in the future.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  • Alam M, Barrett KC, Hodapp RM, Arndt KA. Botulinum toxin and the facial feedback hypothesis: can looking better make you feel happier? J Am Acad Dermatol. 2008;58:1061–72. doi:10.1016/j.jaad.2007.10.649.

    Article  PubMed  Google Scholar 

  • Ascher B, Talarico S, Cassuto D, Escobar S, Hexsel D, Jaén P, et al. International consensus recommendation on the aesthetic usage of botulinum toxin type A (Speywood unit)-part one: upper facial wrinkles. J Eur Acad Dermatol Venereol. 2010;24(11):1278–84. doi:10.1111/j.1468-3083.2010.03631.x.

    Article  CAS  PubMed  Google Scholar 

  • Bartoli D, Battisti A, Cassoni A, Terenzi V, Della Monaca M, Pagnoni M, et al. Contralateral botulinum injections in patients with residual facial asymmetry and contralateral hyperkinesis after primary facial palsy surgery. Ann Ital Chir. 2015;86(3):201–6.

    PubMed  Google Scholar 

  • Benedetto AV. Asymmetrical smiles corrected by botulinum toxin serotype A. Dermatol Surg. 2007;33(1 Spec No):S32–6. doi: 10.1111/j.1524-4725.2006.32329.x.

    Article  CAS  PubMed  Google Scholar 

  • Bessa GR, Grazziotin TC, Manzoni AP, Weber MP, Bonamigo RR. Hailey-Hailey disease treatment with botulinum toxin type A. An Bras Dermatol. 2010;85(5):717–22.

    Article  PubMed  Google Scholar 

  • Bhattacharjee K, Singh M, Bhattacharjee H. Extended effect after a single dose of type A botulinum toxin for asymmetric masseter muscle hypertrophy. Indian J Plast Surg. 2015;48(2):196–9. doi:10.4103/0970-0358.163061.

    Article  PubMed  PubMed Central  Google Scholar 

  • Bloom BS, Payongayong L, Mourin A, Goldberg DJ. Impact of intradermal abobotulinumtoxinA on facial erythema of rosacea. Dermatol Surg. 2015;41 Suppl 1:S9–16. doi:10.1097/DSS.0000000000000277.

    Article  CAS  PubMed  Google Scholar 

  • Carruthers JD, Carruthers JA. Treatment of glabellar frown lines with C. botulinum-A exotoxin. J Dermatol Surg Oncol. 1992;18(1):17–21.

    Article  CAS  PubMed  Google Scholar 

  • Carruthers J, Carruthers A. The effect of full-face broadband light treatments alone and in combination with bilateral crow’s feet botulinum toxin type A chemodenervation. Dermatol Surg. 2004;30(3):355–66.

    PubMed  Google Scholar 

  • Carruthers JD, Glogau RG, Blitzer A. Advances in facial rejuvenation: botulinum toxin type A, hyaluronic acid dermal fillers, and combination therapies-consensus recommendations. Plast Reconstr Surg. 2008;121(5 Suppl):5S–30. doi:10.1097/PRS.0b013e31816de8d0.

    Article  CAS  PubMed  Google Scholar 

  • Carruthers A, Carruthers J, Monheit G, Davis P, Tardie G. Multicenter, randomized, parallel-group study of the safety and effectiveness of onabotulinumtoxinA and hyaluronic acid dermal fillers (24-mg/mL smooth, cohesive gel) alone and in combination for lower facial rejuvenation. Dermatol Surg. 2010;36:2121–34. doi:10.1111/j.1524-4725.2010.01705.x.

    Article  CAS  PubMed  Google Scholar 

  • Cha YR, Kim YG, Kim JH, Kim ST. Effect of unilateral injection of botulinum toxin on lower facial asymmetry as evaluated using three-dimensional laser scanning. Dermatol Surg. 2013;39(6):900–6. doi:10.1111/dsu.12171.

    Article  CAS  PubMed  Google Scholar 

  • Chang CS, Wallace CG, Hsiao YC, Chang CJ, Chen PK. Botulinum toxin to improve results in cleft lip repair: a double-blinded, randomized, vehicle-controlled clinical trial. PLoS One. 2014;9(12), e115690. doi:10.1371/journal.pone.0115690. eCollection 2014.

    Article  PubMed  PubMed Central  Google Scholar 

  • Chiaravalloti A, Payette M. Hailey-Hailey disease and review of management. J Drugs Dermatol. 2014;13(10):1254–7.

    CAS  PubMed  Google Scholar 

  • Coleman KR, Carruthers J. Combination therapy with BOTOX and fillers: the new rejuvenation paradigm. Dermatol Ther. 2006;19(3):177–88. doi:10.1111/j.1529-8019.2006.00072.x.

    Article  PubMed  Google Scholar 

  • Davis SA, Feldman SR, McMichael AJ. Management of keloids in the United States, 1990–2009: an analysis of the National Ambulatory Medical Care Survey. Dermatol Surg. 2013;39(7):988–94. doi:10.1111/dsu.12182.

    Article  CAS  PubMed  Google Scholar 

  • Dayan SH, Ashourian N. Considerations for achieving a natural face in cosmetic procedures. JAMA Facial Plast Surg. 2015;17(6):395. doi:10.1001/jamafacial.2015.1004.

    Article  PubMed  Google Scholar 

  • Dayan SH, Pritzker RN, Arkins JP. A new treatment regimen for rosacea: onabotulinumtoxinA. J Drugs Dermatol. 2012;11(12):e76–9.

    PubMed  Google Scholar 

  • de Maio M. Ethnic and gender considerations in the use of facial injectables: male patients. Plast Reconstr Surg. 2015;136(5 Suppl):40S–3. doi:10.1097/PRS.0000000000001729.

    Article  PubMed  Google Scholar 

  • Fedorowicz Z, van Zuuren EJ, Schoones J. Botulinum toxin for masseter hypertrohphy. Cochrane Database Syst Rev. 2013;9:CD007510. doi:10.1002/14651858.CD007510.pub3.

    Google Scholar 

  • Finzi E, Rosenthal NE. Treatment of depression with onabotulinumtoxinA: a randomized, double-blind, placebo controlled trial. J Psychiatr Res. 2014;52:1–6. doi:10.1016/j.jpsychires.2013.11.006.

    Article  PubMed  Google Scholar 

  • Finzi E, Wasserman E. Treatment of depression with botulinum toxin A: a case series. Dermatol Surg. 2006;32(5):645–9; discussion 649–50. doi:10.1111/j.1524-4725.2006.32136.x.

    CAS  PubMed  Google Scholar 

  • Fregene A, Ditmars D, Siddiqui A. Botulinum toxin type A: a treatment option for digital ischemia in patients with Raynaud’s phenomenon. J Hand Surg [Am]. 2009;34(3):446–52. doi:10.1016/j.jhsa.2008.11.026.

    Article  Google Scholar 

  • Gassia V, Raspaldo H, Niforos FR, Michaud T. Global 3-dimensional approach to natural rejuvenation: recommendations for perioral, nose, and ear rejuvenation. J Cosmet Dermatol. 2013;12(2):123–36. doi:10.1111/jocd.12035.

    Article  PubMed  Google Scholar 

  • Gassner HG, Brissett AE, Otley CC, Boahene DK, Boggust AJ, Weaver AL, et al. Botulinum toxin to improve facial wound healing: a prospective, blinded, placebo-controlled study. Mayo Clin Proc. 2006;81(8):1023–8. doi:10.4065/81.8.1023.

    Article  CAS  PubMed  Google Scholar 

  • Gauglitz GG, Bureik D, Dombrowski Y, Pavicic T, Ruzicka T, Schauber J. Botulinum toxin A for the treatment of keloids. Skin Pharmacol Physiol. 2012;25(6):313–8. doi:10.1159/000342125.

    Article  CAS  PubMed  Google Scholar 

  • Haubner F, Ohmann E, Müller-Vogt U, Kummer P, Strutz J, Gassner HG. Effects of botulinum toxin a on cytokine synthesis in a cell culture model of cutaneous scarring. Arch Facial Plast Surg. 2012;14(2):122–6. doi:10.1001/archfacial.2011.734.

    Article  PubMed  Google Scholar 

  • Haubner F, Leyh M, Ohmann E, Sadick H, Gassner HG. Effects of botulinum toxin A on patient-specific keloid fibroblasts in vitro. Laryngoscope. 2014;124(6):1344–51. doi:10.1002/lary.24456.

    Article  CAS  PubMed  Google Scholar 

  • Heckmann M, Teichmann B, Schröder U, Sprengelmeyer R, Ceballos-Baumann AO. Pharmacologic denervation of frown muscles enhances baseline expression of happiness and decreases baseline expression of anger, sadness, and fear. J Am Acad Dermatol. 2003;49(2):213–6. doi:10.1067/S0190-9622(03)00909-5.

    Article  PubMed  Google Scholar 

  • Hexsel D. Combining procedures with botulinum toxin in dermatology and dermatological surgery. In: Hexsel D, Almeida AT, editors. Cosmetic use of botulinum toxin. São Paulo: AGE; 2002. p. 211–5.

    Google Scholar 

  • Hexsel D, Brum C, Siega C, Schilling-Souza J, Dal’Forno T, Heckmann M, et al. Evaluation of self-esteem and depression symptoms in depressed and nondepressed subjects treated with onabotulinumtoxinA for glabellar lines. Dermatol Surg. 2013;39(7):1088–96. doi:10.1111/dsu.12175.

    Article  CAS  PubMed  Google Scholar 

  • Ho D, Jagdeo J. Successful botulinum toxin (onabotulinumtoxinA) treatment of Hailey-Hailey disease. J Drugs Dermatol. 2015;14(1):68–70.

    PubMed  Google Scholar 

  • Hohl D, Mauro T, Görög JP. Genodermatoses: Darier’s disease and Hailey-Hailey disease. In: Bolognia JL, Jorizzo JL, Rapini R, editors. Dermatology. vol. I. Edinburgh: Mosby; 2003. p. 823–33.

    Google Scholar 

  • Iorio ML, Masden DL, Higgins JP. Botulinum toxin A treatment of Raynaud’s phenomenon: a review. Semin Arthritis Rheum. 2012;41(4):599–603. doi:10.1016/j.semarthrit.2011.07.006.

    Article  CAS  PubMed  Google Scholar 

  • Iozzo I, Tengattini V, Antonucci VA. Multipoint and multilevel injection technique of botulinum toxin A in facial aesthetics. J Cosmet Dermatol. 2014;13(2):135–42. doi:10.1111/jocd.12090.

    Article  PubMed  Google Scholar 

  • Jeong HS, Lee BH, Sung HM, Park SY, Ahn DK, Jung MS, et al. Effect of Botulinum toxin type A on differentiation of fibroblasts derived from scar tissue. Plast Reconstr Surg. 2015;136(2):171e–8. doi:10.1097/PRS.0000000000001438.

    Article  CAS  PubMed  Google Scholar 

  • Katon WJ. Epidemiology and treatment of depression in patients with chronic medical illness. Dialogues Clin Neurosci. 2011;13:7–23.

    PubMed  Google Scholar 

  • Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289(23):3095–105. doi:10.1001/jama.289.23.3095.

    Article  PubMed  Google Scholar 

  • Khan TT, Herne K, Dayan SH, Woodward JA. Facial blanching due to neurotoxins: proposed mechanisms. Dermatol Surg. 2013;39(1 Pt 1):24–9. doi:10.1111/dsu.12057.

    Article  CAS  PubMed  Google Scholar 

  • Kim YS, Lee HJ, Cho S, Lee JD, Kim HS. Early postoperative treatment of thyroidectomy scars using botulinum toxin: a split-scar, double-blind randomized controlled trial. Wound Repair Regen. 2014;22(5):605–12. doi:10.1111/wrr.12204.

    Article  PubMed  Google Scholar 

  • Klein FH, Brenner FM, Sato MS, Robert FM, Helmer KA. Lower facial remodeling with botulinum toxin type A for the treatment of masseter hypertrophy. An Bras Dermatol. 2014;89(6):878–84. doi:10.1590/abd1806-4841.20143200.

    Article  PubMed  PubMed Central  Google Scholar 

  • Koeyers WJ, Van Der Geer S, Krekels G. Botulinum toxin type A as an adjuvant treatment modality for extensive Hailey-Hailey disease. J Dermatolog Treat. 2008;19(4):251–4. doi:10.1080/09546630801955135.

    Article  CAS  PubMed  Google Scholar 

  • Kruger TH, Wollmer MA. Depression – an emerging indication for botulinum toxin treatment. Toxicon. 2015; pii: S0041-0101(15)30094-5. doi: 10.1016/j.toxicon.2015.09.035.

    Google Scholar 

  • Landau M. Combination of chemical peelings with botulinum toxin injections and dermal fillers. J Cosmet Dermatol. 2006;5(2):121–6. doi:10.1111/j.1473-2165.2006.00237.x.

    Article  PubMed  Google Scholar 

  • Lapiere JC, Hirsh A, Gordon KB, Cook B, Montalvo A. Botulinum toxin type A for the treatment of axillary Hailey-Hailey disease. Dermatol Surg. 2000;26(4):371–4.

    Article  CAS  PubMed  Google Scholar 

  • Lee DH, Jin SP, Cho S, Feneran A, Youn CS, Won CH, et al. RimabotulinumtoxinB versus onabotulinumtoxinA in the treatment of masseter hypertrophy: a 24-week double-blind randomized split-face study. Dermatology. 2013;226(3):227–32. doi:10.1159/000349984.

    Article  CAS  PubMed  Google Scholar 

  • Lewis MB, Bowler PJ. Botulinum toxin cosmetic therapy correlates with a more positive mood. Cosmet Dermatol. 2009;8(1):24–6. doi:10.1111/j.1473-2165.2009.00419.x.

    Article  Google Scholar 

  • Li ZJ, Park SB, Sohn KC, Lee Y, Seo YJ, Kim CD, et al. Regulation of lipid production by acetylcholine signalling in human sebaceous glands. J Dermatol Sci. 2013;72(2):116–22. doi:10.1016/j.jdermsci.2013.06.009.

    Article  CAS  PubMed  Google Scholar 

  • López-Ferrer A, Alomar A. Botulinum toxin A for the treatment of familial benign pemphigus. Actas Dermosifiliogr. 2012;103(6):532–5. doi:10.1016/j.ad.2011.05.015.

    Article  PubMed  Google Scholar 

  • Magid M, Reichenberg JS, Poth PE, Robertson HT, LaViolette AK, Kruger TH, et al. Treatment of major depressive disorder using botulinum toxin A: a 24-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2014;75(8):837–44. doi:10.4088/JCP.13m08845.

    Article  CAS  PubMed  Google Scholar 

  • Min P, Xi W, Grassetti L, Trisliana Perdanasari A, Torresetti M, Feng S, et al. Sebum production alteration after Botulinum toxin type A injections for the treatment of forehead rhytides: a prospective randomized double-blind dose-comparative clinical investigation. Aesthet Surg J. 2015;35(5):600–10. doi:10.1093/asj/sju150.

    Article  PubMed  Google Scholar 

  • Motegi SI, Yamada K, Toki S, Uchiyama A, Kubota Y, Nakamura T, Ishikawa O. Beneficial effect of botulinum toxin A on Raynaud’s phenomenon in Japanese patients with systemic sclerosis: a prospective, case series study. J Dermatol. 2015. doi:10.1111/1346-8138.13030.

    Google Scholar 

  • Neumeister MW. Botulinum toxin type A in the treatment of Raynaud’s phenomenon. J Hand Surg [Am]. 2010;35(12):2085–92. doi:10.1016/j.jhsa.2010.09.019.

    Article  Google Scholar 

  • Oh YJ, Lee NY, Suh DH, Koh JS, Lee SJ, Shin MK. A split-face study using botulinum toxin type B to decrease facial erythema index. J Cosmet Laser Ther. 2011;13(5):243–8. doi:10.3109/14764172.2011.613479.

    Article  PubMed  Google Scholar 

  • Park KY, Hyun MY, Jeong SY, Kim BJ, Kim MN, Hong CK. Botulinum toxin for the treatment of refractory erythema and flushing of rosacea. Dermatology. 2015;230:299–301. doi:10.1159/000368773.

    Article  CAS  PubMed  Google Scholar 

  • Prodromidou A, Frountzas M, Vlachos DE, Vlachos GD, Bakoyiannis I, Perrea D, et al. Botulinum toxin for the prevention and healing of wound scars: a systematic review of the literature. Plast Surg (Oakv). 2015;23(4):260–4.

    Google Scholar 

  • Raspaldo H, Niforos FR, Gassia V, Dallara JM, Bellity P, Baspeyras M, et al. Lower-face and neck antiaging treatment and prevention using onabotulinumtoxin A: the 2010 multidisciplinary French consensus – part 2. J Cosmet Dermatol. 2011;10(2):131–49. doi:10.1111/j.1473-2165.2011.00560.x.

    Article  PubMed  Google Scholar 

  • Rose AE, Goldberg DJ. Safety and efficacy of intradermal injection of botulinum toxin for the treatment of oily skin. Dermatol Surg. 2013;39(3 Pt 1):443–8. doi:10.1111/dsu.12097.

    Article  CAS  PubMed  Google Scholar 

  • Saber M, Brassard D, Benohanian A. Inverse psoriasis and hyperhidrosis of the axillae responding to botulinum toxin type A. Arch Dermatol. 2011;147(5):629–30. doi:10.1001/archdermatol.2011.111.

    Article  PubMed  Google Scholar 

  • Sadiq SA, Khwaja S, Saeed SR. Botulinum toxin to improve lower facial symmetry in facial nerve palsy. Eye(Lond). 2012;26(11):1431–6. doi:10.1038/eye.2012.189.

    CAS  Google Scholar 

  • Semchyshyn NL, Kilmer SL. Does laser inactivate botulinum toxin? Dermatol Surg. 2005;31(4):399–404.

    Article  CAS  PubMed  Google Scholar 

  • Serri J, Legré R, Veit V, Guardia C, Gay AM. Botulinum toxin type A contribution in the treatment of Raynaud’s phenomenon due to systemic sclerosis. Ann Chir Plast Esthet. 2013;58(6):658–62. doi:10.1016/j.anplas.2011.11.001.

    Article  CAS  PubMed  Google Scholar 

  • Shaarawy E, Hegazy RA, Abdel Hay RM. Intralesional botulinum toxin type A equally effective and better tolerated than intralesional steroid in the treatment of keloids: a randomized controlled trial. J Cosmet Dermatol. 2015;14(2):161–6. doi:10.1111/jocd.12134.

    Article  PubMed  Google Scholar 

  • Shah AR. Use of intradermal botulinum toxin to reduce sebum production and facial pore size. J Drugs Dermatol. 2008;7(9):847–50.

    PubMed  Google Scholar 

  • Steinsapir KD, Rootman D, Wulc A, Hwang C. Cosmetic microdroplet Botulinum toxin A forehead lift: a new treatment paradigm. Ophthal Plast Reconstr Surg. 2015;31(4):263–8. doi:10.1097/IOP.0000000000000282.

    Article  PubMed  Google Scholar 

  • Sterodimas A, Nicolaou M, Paes TR. Successful use of Botulinum toxin-A for the treatment of neck and anterior chest wall flushing. Clin Exp Dermatol. 2003;28(6):592–4.

    Article  CAS  PubMed  Google Scholar 

  • Tiryaki T, Ciloglu NS. Eyebrow asymmetry: definition and symmetrical correction using botulinum toxin A. Aesthet Surg J. 2007;27(5):513–7. doi:10.1016/j.asj.2007.06.005.

    Article  CAS  PubMed  Google Scholar 

  • Tollefson TT, Senders CM, Sykes JM, Byorth PJ. Botulinum toxin to improve results in cleft lip repair. Arch Facial Plast Surg. 2006;8(3):221–2. doi:10.1001/archfaci.8.3.221.

    Article  PubMed  Google Scholar 

  • Uppal L, Dhaliwal K, Butler PE. A prospective study of the use of botulinum toxin injections in the treatment of Raynaud’s syndrome associated with scleroderma. J Hand Surg Eur Vol. 2014;39(8):876–80. doi:10.1177/1753193413516242.

    Article  CAS  PubMed  Google Scholar 

  • Van de Kerkhof. Psoriasis. In: Bolognia JL, Jorizzo JL, Rapini R, editors. Dermatology. vol. I. Edinburgh: Mosby; 2003. p. 125–49.

    Google Scholar 

  • Walling HW. Primary hyperhidrosis increases the risk of cutaneous infection: a case–control study of 387 patients. J Am Acad Dermatol. 2009;61(2):242–6. doi:10.1016/j.jaad.2009.02.038.

    Article  PubMed  Google Scholar 

  • Wang G, Li C, Gao T, Liu Y. Clinical analysis of 48 cases of inverse psoriasis: a hospital-based study. Eur J Dermatol. 2005;15(3):176–8.

    PubMed  Google Scholar 

  • Weinkle AP, Doktor V, Emer J. Update on the management of rosacea. Clin Cosmet Investig Dermatol. 2015;8:159–77. doi:10.2147/CCID.S58940. eCollection 2015.

    CAS  PubMed  PubMed Central  Google Scholar 

  • Wilkin J, Dahl M, Detmar M, Drake L, Liang MH, Odom R, Powell F, National Rosacea Society Expert Committee. Standard grading system for rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol. 2004;50(6):907–12. doi:10.1016/j.jaad.2004.01.048.

    Article  PubMed  Google Scholar 

  • Williams DR, González HM, Neighbors H, Nesse R, Abelson JM, Sweetman J, et al. Prevalence and distribution of major depressive disorder in African Americans, Caribbean blacks, and non-Hispanic whites: results from the national survey of American life. Arch Gen Psychiatry. 2007;64(3):305–15. doi:10.1001/archpsyc.64.3.305.

    Article  PubMed  Google Scholar 

  • Wollmer MA, de Boer C, Kalak N, Beck J, Götz T, Schmidt T, et al. Facing depression with botulinum toxin: a randomized controlled trial. J Psychiatr Res. 2012;46(5):574–81. doi:10.1016/j.jpsychires.2012.01.027.

    Article  PubMed  Google Scholar 

  • WT W. Microbotox of the lower face and neck: evolution of a personal technique and its clinical effects. Plast Reconstr Surg. 2015;136(5 Suppl):92S–100. doi:10.1097/PRS.0000000000001827.

    Google Scholar 

  • Xiao Z, Zhang F, Cui Z. Treatment of hypertrophic scars with intralesional botulinum toxin type A injections: a preliminary report. Aesthetic Plast Surg. 2009;33(3):409–12. doi:10.1007/s00266-009-9334-z.

    Article  PubMed  Google Scholar 

  • Xiao Z, Zhang F, Lin W, Zhang M, Liu Y. Effect of botulinum toxin type A on transforming growth factor beta1 in fibroblasts derived from hypertrophic scar: a preliminary report. Aesthetic Plast Surg. 2010;34(4):424–7. doi:10.1007/s00266-009-9423-z.

    Article  PubMed  Google Scholar 

  • Xiao Z, Zhang M, Liu Y, Ren L. Botulinum toxin type a inhibits connective tissue growth factor expression in fibroblasts derived from hypertrophic scar. Aesthetic Plast Surg. 2011;35(5):802–7. doi:10.1007/s00266-011-9690-3.

    Article  PubMed  Google Scholar 

  • Xiaoxue W, Xi C, Zhibo X. Effects of botulinum toxin type A on expression of genes in keloid fibroblasts. Aesthet Surg J. 2014;34(1):154–9. doi:10.1177/1090820X13482938.

    Article  PubMed  Google Scholar 

  • Yuraitis M, Jacob CI. Botulinum toxin for the treatment of facial flushing. Dermatol Surg. 2004;30(1):102–4.

    PubMed  Google Scholar 

  • Zanchi M, Favot F, Bizzarini M, Piai M, Donini M, Sedona P. Botulinum toxin type-A for the treatment of inverse psoriasis. J Eur Acad Dermatol Venereol. 2008;22(4):431–6. doi:10.1111/j.1468-3083.2007.02457.x.

    Article  CAS  PubMed  Google Scholar 

  • Zhang X, Hu Y, Nie Z, Song Y, Pan Y, Liu Y, Jin L. Treatment of Raynaud’s phenomenon with botulinum toxin type A. Neurol Sci. 2015;36(7):1225–31. doi:10.1007/s10072-015-2084-6.

    Article  PubMed  Google Scholar 

  • Zhao H, Lian Y. Clinical and image improvement of Raynaud’s phenomenon after botulinum toxin type A treatment. Australas J Dermatol. 2015;56(3):202–5. doi:10.1111/ajd.12326.

    Article  CAS  PubMed  Google Scholar 

  • Zhibo X, Miaobo ZJ. Botulinum toxin type A affects cell cycle distribution of fibroblasts derived from hypertrophic scar. J Plast Reconstr Aesthet Surg. 2008;61(9):1128–9. doi:10.1016/j.bjps.2008.05.003.

    Article  PubMed  Google Scholar 

  • Ziade M, Domergue S, Batifol D, Jreige R, Sebbane M, Goudot P, et al. Use of botulinum toxin type A to improve treatment of facial wounds: a prospective randomised study. J Plast Reconstr Aesthet Surg. 2013;66(2):209–14. doi:10.1016/j.bjps.2012.09.012.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Brazilian Center for Studies in Dermatology, Dom Pedro II 1592, Porto Alegre / Rio de Janeiro, RS / RJ, 90570-040, Brazil

    Doris Hexsel

  2. Hexsel Dermatology Clinic, Porto Alegre, Rio de Janeiro, Brazil

    Doris Hexsel

  3. Brazilian Center for Studies in Dermatology, Porto Alegre, Brazil

    Patricia Caspary & Carolina Siega

Authors
  1. Doris Hexsel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patricia Caspary
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Carolina Siega
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Doris Hexsel .

Editor information

Editors and Affiliations

  1. Universidade Federal Fluminense, Niterói, São Paulo, Brazil

    Maria Claudia Almeida Issa

  2. Lexbios Medica S/S, São Paulo, São Paulo, Brazil

    Bhertha Tamura

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this entry

Cite this entry

Hexsel, D., Caspary, P., Siega, C. (2017). Botulinum Toxin for New Indications. In: Issa, M., Tamura, B. (eds) Botulinum Toxins, Fillers and Related Substances. Clinical Approaches and Procedures in Cosmetic Dermatology. Springer, Cham. https://doi.org/10.1007/978-3-319-20253-2_14-2

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-20253-2_14-2

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-20253-2

  • Online ISBN: 978-3-319-20253-2

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Chapter history

  1. Latest

    Botulinum Toxin for New Indications
    Published:
    02 January 2019

    DOI: https://doi.org/10.1007/978-3-319-20253-2_14-3

  2. Botulinum Toxin for New Indications
    Published:
    17 May 2017

    DOI: https://doi.org/10.1007/978-3-319-20253-2_14-2

  3. Original

    Toxin for New Indications
    Published:
    21 November 2016

    DOI: https://doi.org/10.1007/978-3-319-20253-2_14-1

Search

Navigation